Caprock Group LLC Invests $515,000 in Haleon PLC Sponsored ADR $HLN

Caprock Group LLC bought a new stake in Haleon PLC Sponsored ADR (NYSE:HLN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 52,181 shares of the company’s stock, valued at approximately $515,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. JTC Employer Solutions Trustee Ltd boosted its stake in shares of Haleon by 120.7% in the 3rd quarter. JTC Employer Solutions Trustee Ltd now owns 712,229 shares of the company’s stock valued at $6,392,000 after purchasing an additional 389,467 shares during the last quarter. Arlington Partners LLC boosted its stake in Haleon by 128.0% in the third quarter. Arlington Partners LLC now owns 508,886 shares of the company’s stock valued at $4,565,000 after acquiring an additional 285,692 shares during the last quarter. Archford Capital Strategies LLC bought a new position in Haleon in the third quarter valued at approximately $2,149,000. New York State Common Retirement Fund acquired a new stake in Haleon during the 2nd quarter worth $3,964,000. Finally, Acadian Asset Management LLC raised its position in shares of Haleon by 3,031.5% during the 2nd quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock valued at $55,813,000 after acquiring an additional 5,212,711 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Up 0.3%

Shares of Haleon stock opened at $11.23 on Wednesday. The company has a market capitalization of $50.01 billion, a P/E ratio of 28.80 and a beta of 0.19. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. The business has a 50-day moving average of $10.25 and a two-hundred day moving average of $9.73. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on HLN shares. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Haleon from a “hold” rating to a “sell” rating in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Haleon has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.